Next |
home / stock / iova / iova message board
Subject | By | Source | When |
---|---|---|---|
Citing feedback, the company announced that the design | jondoeuk | investorshub | 07/10/2023 5:02:29 PM |
$IOVA Price gaining | Watts Watt | investorshub | 07/10/2023 5:37:07 AM |
Do we have a winner?Turn around time? | jondoeuk | investorshub | 07/08/2023 7:59:28 AM |
$IOVA Lets go go go go... Up up and away we go. | Watts Watt | investorshub | 07/05/2023 10:58:06 PM |
$IOVA bulls and bears | jondoeuk | investorshub | 07/05/2023 5:31:05 PM |
(OT): The importance of CD4+ T-cells https://aacrjournals.org/clincancerres/arti | jondoeuk | investorshub | 07/05/2023 12:26:26 AM |
$IOVA The now | Watts Watt | investorshub | 06/30/2023 9:57:52 PM |
where is the squeeze? | ClayTrader | investorshub | 06/30/2023 7:49:12 PM |
Price now | jondoeuk | investorshub | 06/25/2023 12:55:42 PM |
In addition, use a manufacturing process that promises | jondoeuk | investorshub | 06/25/2023 12:09:45 AM |
They combined the CRISPRomics platform with CRISPR2 tech, | jondoeuk | investorshub | 06/25/2023 12:08:01 AM |
(OT): KSQ Therapeutics is working on gene-edited TIL | jondoeuk | investorshub | 06/25/2023 12:04:59 AM |
MomentumIts now | ClayTrader | investorshub | 06/24/2023 11:22:11 PM |
ImmuT Finder is a novel T-cell immunoregulatory target | jondoeuk | investorshub | 06/23/2023 11:30:19 PM |
Preclinical data https://ascopubs.org/doi/10.1200/JCO.2021.39.15 suppl.e14506 https://aacrjournals.o | jondoeuk | investorshub | 06/23/2023 11:23:58 PM |
(OT): GRIT Bio was founded in 2019 and | jondoeuk | investorshub | 06/23/2023 11:19:55 PM |
$IOVA we got news | Porterhouse10 | investorshub | 06/17/2023 1:49:41 AM |
$IOVA Price gaining | jondoeuk | investorshub | 06/15/2023 11:37:04 PM |
$IOVA The now | dinogreeves | investorshub | 06/15/2023 1:54:42 AM |
what do you make of this data? | jondoeuk | investorshub | 06/14/2023 11:00:51 PM |
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, In...
2024-06-28 04:05:00 ET Earlier this year, share prices of Iovance Biotherapeutics (NASDAQ: IOVA) were soaring after one of its therapies obtained approval from regulators. Iovance stock would go on to reach share price highs of more than $18. Today, however, the stock trades at less...
2024-06-20 07:00:08 ET Reni Benjamin from JMP Securities issued a price target of $23.00 for IOVA on 2024-06-20 06:20:00. The adjusted price target was set to $23.00. At the time of the announcement, IOVA was trading at $8. The overall price target consensus is at $23.83...